APA

Anraku T., Kuroki H., Kazama A., Bilim V., Tasaki M., Schmitt D., Mazar A., Giles F. J., Ugolkov A. & Tomita Y. (20200911). Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. : International journal of molecular medicine.

Chicago

Anraku Tsutomu, Kuroki Hiroo, Kazama Akira, Bilim Vladimir, Tasaki Masaaki, Schmitt Daniel, Mazar Andrew, Giles Francis J, Ugolkov Andrey and Tomita Yoshihiko. 20200911. Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. : International journal of molecular medicine.

Harvard

Anraku T., Kuroki H., Kazama A., Bilim V., Tasaki M., Schmitt D., Mazar A., Giles F. J., Ugolkov A. and Tomita Y. (20200911). Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. : International journal of molecular medicine.

MLA

Anraku Tsutomu, Kuroki Hiroo, Kazama Akira, Bilim Vladimir, Tasaki Masaaki, Schmitt Daniel, Mazar Andrew, Giles Francis J, Ugolkov Andrey and Tomita Yoshihiko. Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer. : International journal of molecular medicine. 20200911.